19
Aug
2021
17:00
BST
12:00
EST
Webinar
Supersaturated Oxygen Therapy (SSO2): The Next Frontier in STEMI Treatment
-
Views:
6039
-
Likes:
9
Overview
Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years. With 90% of coronary blood flow in the capillaries, the answer might be in the microvasculature.(1) TherOx SSO2 Therapy is the first FDA approved therapy shown to significantly reduce infarct size in STEMI patients.(2) Pre-clinical studies showed that SSO2 improves microvascular flow, which is strongly associated with mortality and hospitalization for HF within 1 year.(3),(4)
Learn about the mechanism and data around SSO2 Therapy for STEMI patients.
(1) Kaul S, et al. Circulation. 2004;109:146–149.
(2) SSO2 Therapy is indicated for use in anterior STEMI patients immediately following primary PCI completed within 6 hours of symptoms onset.
(3) Spears, et al. J Invas Cardiol 2002;14:160-6.
(4) DeWaha, et al. European Heart Journal (2017) 38, 3502–3510.
To find out more about SSO2 Therapy, visit: https://info.zoll.com/contact-a-product-expert-for-therox-sso2-therapy-zoll
Faculty:
Gregg Stone
Robert Kloner
This webinar is supported by
Agenda
Learning Objectives
- To develop an understanding of trends in STEMI treatment
- To understand the role of microvascular obstruction in outcomes
- To develop an understanding of SSO2 therapy impact
- To better understand SSO2 therapy data
Target Audience
- Interventional Cardiologists
- Heart Failure Specialists
Faculty Biographies
Gregg Stone
Dr Stone is a leading expert in interventional cardiology and is one of the most widely cited researchers in science.
Robert Kloner
Robert Kloner is Chief Science Officer and Scientific Director of Cardiovascular Research at Huntington Medical Research Institutes (HMRI). He serves as Professor of Medicine (Clinical Scholar) at Keck School of Medicine at the University of Southern California.